Please take the following THREE STEPS in order to fully participate in this event.
Take the time now to register on this Myeloma Crowd page and join us on November 15th at 3 PM Eastern as we host a Q&A session with Nobel Prize Laureate winner and immunotherapy pioneer, Dr. Jim Allison, and his genius wife, Dr. Padmanee Sharma, a renowned genitourinary cancer doctor. Both Drs. Allison and Sharma currently practice at MD Anderson Cancer Center in Houston, Texas. You can register for the event with Drs. Allison and Sharma by clicking the orange registration button above.
After signing up for the Q&A session, now it's time to watch the documentary. You can access the documentary, Jim Allison: Breakthrough, for free before November 14th, 2021.
The free link to the documentary will be distributed on November 1st. If you sign up for documentary access before that date, it will be sent automatically to you. If you sign up for free access after November 1st, the free link to the documentary will be sent to you right away.
Register to access the documentary for free here: Register to Get Free Access to the Documentary Jim Allison: Breakthrough
All questions for this event must be submitted by November 12th. No questions submitted during the meeting will be answered.
Please submit your questions here: Questions for the Jim Allison: Breakthrough Q&A Event
We are so excited for you to join us. Please share with any family or friends that might be interested!
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.
Dr. James Allison is Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. He earned the 2018 Nobel Prize in Physiology or Medicine, which he shared with Dr. Tasuku Honjo, "for their discovery of cancer therapy by inhibition of negative immune regulation." Among his most notable discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naïve T cells and prevents anergy in T cell clones. His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models. This finding and a great deal of persistence paved the way for the field of immune checkpoint blockade therapy for cancer. Work in his lab led to the development of ipilimumab, an antibody to human CTLA-4 and the first immune checkpoint blockade therapy approved by the FDA. Among many honors, he is a member of the National Academies of Science and Medicine and received the Lasker-Debakey Clinical Medical Research award in 2015. His current work seeks to improve immune checkpoint blockade therapies currently used by our clinicians and identify new targets to unleash the immune system in order to eradicate cancer.
Dr. Padmanee Sharma is a professor of Genitourinary Medical Oncology and Immunology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. She has participated in 54 research outputs since 1996, focusing primarily on immunotherapy in her collaborations with Dr. James P. Allison. Sharma is a Cancer Research Institute Investigator who has tested new prostate cancer immunotherapies, looking for differences in T cell subsets and function between pre-therapy blood and tissue samples versus post-therapy blood and tissue samples. She has won multiple awards during her career including the 2012 MD Anderson Cancer Center Faculty Scholar Award and the 2008 Melanoma Research Alliance Young Investigator Award. With Allison, Sharma is exploring combinations of immunological therapies and targeted drugs in preclinical studies to more effectively treat a variety of cancers.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113